GLP-1 Drugs and Male Pattern Hair Loss, Here’s What the New Study Actually Shows

A new genetic study has been doing the rounds recently under headlines suggesting that weight loss injections could push men towards baldness. The claim is that men who are already genetically prone to male pattern hair loss carry a 7% higher risk of losing their hair if they use GLP-1 drugs like Mounjaro, Wegovy and Ozempic. Moreover, this study also arrives on top of two other ones which all suggest that we can no longer describe hair loss on Ozempic and similar drugs as solely a temporary shedding problem. In this article, we’ll explain what the new study found and what it means for GLP-drug mediated shedding and pattern hair loss. We’ll also explore what you can do if you’re experiencing hair loss whilst on a GLP-1.

What Did the New GLP-1 Hair Loss Study Actually Find?

The study found that men with a genetic tendency to higher GLP-1 receptor activity had about 7% higher odds of male pattern hair loss. This link held up even after adjusting for blood pressure, testosterone and body fat. It was published in the Journal of Investigative Dermatology as a letter to the editor on 3 September 2026 by a team at NYU Grossman School of Medicine. This is the first study to show a genetic link between the GLP-1 pathway and androgenetic alopecia (pattern hair loss).

There’s a catch though, researchers didn’t recruit anyone taking Mounjaro or Wegovy. Instead, they identified 22 genetic variants that naturally increase the amount of GLP-1 receptor protein a person makes. They then checked whether those variants were more common in men with pattern hair loss across a database of 205,327 men and found that they were, by a small margin. The authors say that the findings are evidence that the GLP-1 receptor pathway plays a role in pattern hair loss. However, it does not provide proof of a direct effect of GLP-1 drugs on hair loss. They also describe the effect as modest and its clinical relevance as uncertain.

There is one more finding worth knowing. In an exploratory check, the team reported that the GLP-1 receptor is present in human hair follicles and appears more abundant in scalp that is already losing hair. This is early work, but it gives the genetic result some biological footing. The study also only looked at men, because male pattern hair loss is far better mapped genetically than female pattern hair loss. However, the researchers say the same relationship could apply to women and plan to investigate it.

What is Mendelian Randomisation & Why Does it Matter Here?

This study used Mendelian randomisation. It is a technique that uses the genes you were born with as a stand-in for lifelong exposure to something. So, in this case having higher GLP-1 receptor activity. The reason it matters here is because it changes what a 7% higher risk means.

The idea is fairly simple. You get your genetic variants at conception. This means you can’t change them by your diet, weight or the medicines you take later in life. So, in this study that data shows that men who happen to carry variants that raise GLP-1 receptor levels also have slightly more pattern hair loss suggesting a link between the two. However, the study measures a lifetime of slightly higher receptor activity from birth, which isn’t the same thing as a weekly injection of a drug that switches the receptor on hard for a few years in adulthood. So, whilst genetics can point to a potential link, only a clinical trial of people taking the drug can tell you what the drug does.

There is also a common misreading of the number. A 7% higher risk is a relative figure. It doesn’t mean 7 in every 100 men on Mounjaro or another GLP-1 will go bald. If a man’s chance of noticeable pattern hair loss over a given period were 30%, a 7% relative increase would take it to roughly 32%. That is a real effect at population level, but for an individual man it is a small increase in risk. Interestingly, the study population was almost entirely of European ancestry, so we don’t yet know whether the finding holds in other racial groups.

What Does the Wider 2026 Evidence Say?

Despite it’s limitations, this genetic study is the third piece of evidence this year to suggest hair loss on GLP-1 drugs is more common than on comparable medicines. They also show both male pattern hair loss occurs alongside temporary shedding which initially was thought to be the only form of hair loss that occurs.

In July, a study published in The BMJ compared GLP-1 drugs in over 23,000 adults with type 2 Diabetes against over 16,00 adults using conventional diabetes drugs (SGLT-2 and DPP-4 inhibitors). After adjusting for age, sex, ethnicity, BMI and other conditions, they found that GLP-1 users had a 37% higher risk of hair loss than SGLT-2 users and a 68% higher risk than DPP-4 users.

Crucially, there was also a multicentre cohort study published in JAAD International which looked records from nearly 550,000 patients and found that GLP-1 users had higher odds of both telogen effluvium (temporary shedding) and androgenetic alopecia (pattern hair loss) at 12 months. This was independent of age, sex, BMI and whether they had diabetes. Whilst telogen effluvium is the hair shedding we expect after rapid weight loss, pattern hair loss showing up more often is harder to explain by dieting alone. This is is exactly why the new genetic study is so useful. It now gives a possible mechanism for how some men on GLP-1 drugs might be more vulnerable to developing male pattern hair loss.

What Do the Regulators Say About GLP-1 Drugs and Hair Loss?

Hair loss has been reported with the whole GLP-1 class and so far three regulators have now taken a position. In the UK, the MHRA-approved patient leaflet for Wegovy lists hair loss as a common side effect. NHS patient information for Mounjaro lists hair loss among its most common side effects. The European Medicines Agency’s product information for Wegovy classes hair loss the same way. In the United States, the FDA added hair loss to its list of potential safety signals for GLP-1 receptor agonists in January 2024, covering semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza) and dulaglutide (Trulicity). However, a signal on that list isn’t a confirmed side effect. It means the FDA has judged the reports serious enough to evaluate whether the licence wording needs to change.

The picture does differ from drug to drug, and it helps to be precise about which is which. Semaglutide is available as Ozempic for type 2 diabetes and as Wegovy (injection or tablet) for weight management. Tirzepatide is available as Mounjaro in the UK for both and as Zepbound for weight management in the US. Interestingly, hair loss doesn’t appear in the licence for Ozempic, even though it is the same molecule as Wegovy. This could be because the diabetes trials used lower doses.

How Can I Tell if I have Telogen Effluvium or Pattern Hair Loss?

Telogen effluvium is the body’s response to a shock which includes rapid weight loss and sudden drop in calories and protein. The hair growth cycle responds by pushing far more follicles than usual into the resting phase at once. These hairs then fall out together two to four months after the trigger. The shedding is diffuse across the whole scalp and can look dramatic. However, it usually settles within six months once weight stabilises and eating improves because the hair follicles themselves remain healthy.

Pattern hair loss is a different process that occurs in genetically predisposed individuals. The main driver is DHT, a form of testosterone that makes genetically sensitive follicles shrink over time. Each new hair grows finer and shorter than the last. In men that it usually presents as a receding hairline and a thinning crown. Women usually develop a widening parting and overall loss of hair density with the front hairline preserved. It doesn’t normally shed dramatically and is progress. Unfortunately, it doesn’t get better on its own.

The distinction matters because the two conditions behave differently and need different treatment. Most hair loss on GLP-1 drugs is telogen effluvium, which is temporary. Pattern hair loss is progressive and the new evidence suggests these drugs may unmask or hurry it along in people who were going to develop it anyway. In practice, the two forms of hair loss often overlap with each other.

Should You Stop Your Weight Loss Injection if Your Hair is Thinning?

Do not stop taking medication without talking to the doctor who prescribed it. For most people these medicines are treating something very important to their long-term health such as type 2 diabetes, heart disease risk or obesity itself. What the new evidence does support is a conversation with your doctor before and during your treatment. If you have a strong family history of pattern hair loss, it makes sense to raise it before you start and to agree a plan for monitoring.

The NYU researchers themselves suggest that, if future work confirms the link, it may be possible to screen some men for hair loss risk before starting a GLP-1 drug and offer them preventive treatment such as minoxidil. We are not there yet so for the time-being it is sensible to speak with your doctor if you’re worried about or experiencing hair loss whilst on GLP-1 drugs. There are many ways to help support telogen effluvium recovery as well as treat pattern hair loss.

What Can You Do About Hair Loss on a GLP-1?

The answer depends on which type you have, which is why the first step is working that out and seeking medical help early. In plain terms, effluvium shedding needs time and nutrition whilst pattern hair loss needs treatment. Potential measures for tackling hair loss from GLP-1 drugs include:

• Slow the weight loss: Very rapid loss is the biggest driver of telogen effluvium. Your prescriber may choose to carefully adjust your dose or usage to reduce the rate of weight loss.
• Protect your protein: Appetite suppression makes it easy to under-eat and hair is built from protein. Aim for a source of protein at every meal even when the meals are small.
• Check for deficiencies: Iron, ferritin, vitamin D, zinc and B12 are the usual suspects when intake drops. Luckily, vitamin deficiencies are a correctable cause of shedding. Ask your doctor to check your levels and possibly refer you to a nutritionist.
• Give shedding time: Telogen effluvium recovers on its own once the trigger passes. Regrowth is usually visible within six months and full density can take a year. Treating it with hair growth medication is optional.
• Treat pattern hair loss early: This form of hair loss doesn’t fix itself. The follicles miniaturise a little more with every cycle so early treatment is necessary to prevent irreversible follicle damage and hair loss.

For pattern hair loss, minoxidil prolongs the growth phase and is available over the counter in topical treatments at 2% and 5% strength. Minxidil is also available as an off-label treatment in oral form and in unlicensed compounded topical formulas at higher strengths by prescription. Finasteride and dutasteride lower DHT and are the most effective way to slow the miniaturisation Oral finasteride is licensed for treating pattern hair loss in men whilst topical finasteride and all forms of dutasteride are available as unlicensed prescription treatments for hair loss. Both carry serious side effects that need discussion with your medical provider. Spironolactone is also increasingly used alongside minoxidil in oral form for women and topically for hair loss in both for men and women as an alternative to finasteride and dutatsteride. Again these are off-label unlicensed uses that a doctor or other medical prescriber can provide if appropriate,

So, do GLP-1 drugs cause male pattern hair loss? The most accurate answer today is that they probably can’t cause it on their own. However, they may bring it forward or make it worse in men who were genetically susceptible to getting it anyway. What these drugs certainly do is trigger temporary shedding in some people. The new genetic study is a good piece of science that has been reported with more certainty than its authors intended. In fact, its most useful message isn’t that weight loss injections are bad for your hair. It’s that if you’re on one and your hair is shedding, it is worth finding out which kind of hair loss you’re dealing with so you can manage them appropriately. Always discuss with your doctor if you notice hair loss or any other side effect and seek help early.

At City Skin Clinic, we are passionate about personalised hair loss treatment. Our doctors design custom topical serums for male and female pattern hair loss using actives like minoxidil, finasteride, dutasteride, spironolactone, melatonin and caffeine where appropriate. If you’re you’re experiencing shedding or pattern hair loss, our doctors can build a plan for your needs. Book a video consultation or use our online consultation form. The journey towards great hair starts here.

This article is intended for general informational purposes only and is not a substitute for medical advice, diagnosis or treatment. Always consult a qualified medical provider for any medical concerns or questions you might have.